NCT Number: NCT05245006
Phase: Phase 1
Trial Summary: CD46 is an exciting new therapeutic target in prostate cancer, with the antibody drug conjugate FOR46 under investigation in phase I clinical trials. The hypothesis of the study is – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Robert Flavell, MD, PhD
Acronym:
PET Imaging Study of 89Zr-DFO-YS5 in Men With Prostate Cancer
— PHENTrials.com Increasing Participation in Prostate Cancer Clinical Trials to Save Lives